drugset / Trial / NCT02056756
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
Phase 1/2
Completed
63 enrolled
Stichting European Myeloma Network
Fondazione EMN Italy Onlus · collab
NaSingle-groupOpen-labelTreatment
Summary
Open-label phase Ib/II, multicenter, international non-comparative trial. This study is designed to determine the safety and efficacy of the novel salvage regimen (CBd) followed by a carfilzomib maintenance in patients with relapsed or refractory multiple myeloma. Patients will be evaluated at scheduled visits in up to 4 study periods: pretreatment, treatment, maintenance and long-term follow-up (LTFU).
Timeline
- Start
- 2014-04
- Primary completion
- 2015-09
- Completion
- 2023-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 27 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 36 mg/m2 | Intravenous |
| Subject | Carfilzomib | Other / unclassified | 45 mg/m2 | Intravenous |